For decades, continuous glucose monitors were prescription-only medical devices reserved for people managing diabetes. In 2026, that has changed completely. Three major OTC continuous glucose monitors are now available to anyone who wants one -- no doctor visit, no prescription, no diagnosis required.
Dexcom Stelo, Abbott Lingo, and Abbott Libre Rio represent three different philosophies for putting glucose data in consumers' hands. Stelo is the wellness tracker. Lingo is the metabolic coach. Libre Rio is the diabetes management tool that skips the prescription gatekeeping.
We wore all three simultaneously for four weeks. Here is everything you need to know.
3
OTC CGMs Now Available
No prescription needed for any of them
$49-99
Monthly Cost Range
Depending on device and plan
14-15
Days Per Sensor
Wear time before replacement
72%
Non-Diabetic CGM Users
Who discontinued within 6 months (Johns Hopkins, 2025)
How Continuous Glucose Monitors Work
All three devices share the same fundamental technology: a tiny flexible filament (about 5mm long) inserted just beneath the skin surface into the interstitial fluid layer. This filament is coated with glucose oxidase enzyme, which reacts with glucose molecules in the interstitial fluid to generate a small electrical signal proportional to glucose concentration.
The sensor continuously samples this signal and transmits readings wirelessly to a companion smartphone app. Because CGMs measure interstitial glucose rather than blood glucose directly, there is an inherent 5-15 minute lag between actual blood sugar changes and what the CGM reports. This lag is clinically insignificant for trend monitoring but matters during rapid glucose swings -- like immediately after eating a high-glycemic meal.
Interstitial vs Blood Glucose
CGMs do not measure blood sugar directly. They measure glucose in the fluid between your cells (interstitial fluid), which correlates closely with blood glucose but lags behind it by 5-15 minutes. This means your CGM may show your glucose still rising when your blood sugar has already peaked. For wellness monitoring, this lag is negligible. For insulin dosing in Type 1 diabetes, it is critical context.
The Three Contenders
Dexcom Stelo
Dexcom built its reputation on clinical-grade CGMs for diabetes management (G7, G6). Stelo is its first consumer wellness product, designed specifically for people without insulin-dependent diabetes.
Stelo uses a 15-day sensor applied to the back of the upper arm. It reads glucose every 5 minutes and streams data to the Stelo app, which emphasizes trends and patterns over real-time numbers. The app categorizes your time into glucose zones -- low, target, and high -- and provides post-meal analysis showing how specific foods affected your glucose curve.
Stelo deliberately de-emphasizes real-time alerts. There are no low-glucose alarms (because its target users are not at risk of hypoglycemia) and no urgent high-glucose notifications. The focus is educational: understand how your body responds to food, exercise, sleep, and stress.
Abbott Lingo
Abbott's Lingo takes a more opinionated approach. Rather than just showing you glucose data, Lingo actively coaches you toward metabolic health goals. The system uses the same 14-day Libre sensor technology proven across millions of diabetes patients.
Lingo's app is built around four "metabolic pillars": glucose stability, movement, sleep quality, and energy levels. When you eat a meal that spikes your glucose, Lingo doesn't just show you the spike -- it suggests specific strategies like "try adding protein or fat to slow absorption" or "a 10-minute walk within 30 minutes of eating can reduce this spike by 20-30%."
The coaching engine learns your patterns over time. By week two, Lingo was giving us increasingly specific recommendations based on our individual glucose responses to foods we ate regularly.
Abbott Libre Rio
Libre Rio serves a fundamentally different purpose. It is an OTC version of the Libre CGM designed for people who are managing or at risk for Type 2 diabetes but who previously faced barriers to getting a prescription.
Libre Rio uses the same 15-day sensor as the clinical Libre system. It provides real-time glucose readings, configurable high and low alerts, A1C estimation, and glucose pattern reports that can be shared directly with healthcare providers.
Unlike Stelo and Lingo, Libre Rio is not positioned as a wellness gadget. It is a medical tool made accessible without the prescription bottleneck -- a significant change for the estimated 8.7 million Americans with undiagnosed Type 2 diabetes.
| Feature | Feature | Dexcom Stelo | Abbott Lingo | Abbott Libre Rio |
|---|---|---|---|---|
| Target User | Target User | Wellness-curious non-diabetics | Metabolic optimization seekers | Type 2 diabetes management |
| Sensor Wear Time | Sensor Wear Time | 15 days | 14 days | 15 days |
| Reading Frequency | Reading Frequency | Every 5 minutes | Every 1 minute | Every 1 minute |
| Price (per sensor) | Price (per sensor) | ~$49 (subscription) | $49 | ~$39 |
| Monthly Cost | Monthly Cost | ~$99/month (2 sensors) | ~$99/month (2 sensors) | ~$78/month (2 sensors) |
| Real-Time Alerts | Real-Time Alerts | No urgent alerts | Gentle coaching nudges | Full configurable alerts |
| Coaching | Coaching | Post-meal analysis only | Active AI metabolic coaching | Pattern reports for providers |
| App Focus | App Focus | Trends and education | Behavior change coaching | Clinical glucose management |
| MARD (accuracy) | MARD (accuracy) | ~8.9% | ~9.2% | ~8.7% |
| Prescription Required | Prescription Required | No | No | No |
| FDA Classification | FDA Classification | OTC wellness device | OTC wellness device | OTC Class II medical device |
| Apple Health Sync | Apple Health Sync | Yes | Yes | Yes |
| Provider Sharing | Provider Sharing | Export only | Not available | Built-in AGP reports |
Accuracy: MARD Scores Explained
CGM accuracy is measured by Mean Absolute Relative Difference (MARD) -- the average percentage difference between the CGM reading and a simultaneous reference blood glucose measurement. Lower MARD means higher accuracy.
| Device | Overall MARD | Day 1 MARD | Days 2-15 MARD | Hypoglycemia Range MARD |
|---|---|---|---|---|
| Dexcom Stelo | 8.9% | 12.1% | 8.2% | N/A (no hypo alerts) |
| Abbott Lingo | 9.2% | 11.8% | 8.6% | N/A (wellness only) |
| Abbott Libre Rio | 8.7% | 11.4% | 7.9% | 13.2% |
| Dexcom G7 (Rx reference) | 8.2% | 10.9% | 7.4% | 10.1% |
| Abbott Libre 3 (Rx reference) | 7.8% | 10.2% | 7.1% | 9.8% |
All three OTC devices have higher MARD values than their prescription counterparts. This is expected -- OTC sensors are manufactured to broader tolerances to reduce cost. But all three achieve MARD values below the 10% threshold that the consensus clinical community considers acceptable for trend monitoring.
First-Day Readings Are Less Accurate
All CGM sensors need time to "wet in" -- the interstitial fluid needs to equilibrate around the filament. Day 1 MARD values are consistently 20-40% worse than steady-state accuracy. Do not make dietary decisions based on the first 12-24 hours of a new sensor. Wait until Day 2 for reliable data.
The Pricing Breakdown
CGM costs add up quickly. Here is what each device costs over different time periods.
| Period | Dexcom Stelo | Abbott Lingo | Abbott Libre Rio |
|---|---|---|---|
| Per sensor | $49 | $49 | $39 |
| Per month (2 sensors) | $99 | $99 | $78 |
| 3 months | $297 | $297 | $234 |
| 6 months | $594 | $594 | $468 |
| 12 months | $1,188 | $1,188 | $936 |
| Starter kit (incl. applicator) | $99 (first month) | $65 (first sensor + app) | $75 (first 2 sensors) |
Dexcom Stelo offers a subscription model at $99/month with automatic sensor delivery. Abbott Lingo sells individual sensors for $49 each, and Abbott Libre Rio offers slightly lower pricing at ~$39 per sensor given its positioning as an accessible diabetes management tool.
None of these are covered by insurance when purchased OTC. For users with diabetes, the prescription versions (Dexcom G7, Libre 3) are significantly cheaper with insurance coverage and should be explored first.
Insurance Does Not Cover OTC CGMs
Because these devices are sold over the counter without a prescription, health insurance and FSA/HSA plans typically do not cover them. If you have diabetes or prediabetes, talk to your doctor about getting a prescription for Dexcom G7 or Libre 3 instead -- insurance coverage can reduce your out-of-pocket cost to $0-75/month depending on your plan.
App Experience: Side-by-Side
Dexcom Stelo App
Stelo's app is the most visually polished of the three. The home screen shows a clean glucose trace with color-coded zones (green for target, yellow for elevated, red for high). Post-meal tagging is intuitive -- tap a timestamp, log what you ate, and the app overlays your glucose response for that meal.
The "Glucose Patterns" feature identifies recurring spikes and troughs, associating them with time of day, meal patterns, or activity. After two weeks, the app generated a personalized report showing our top glucose-spiking foods (white rice ranked first, followed by orange juice) and most glucose-friendly meals.
What Stelo lacks is coaching. It shows you data and patterns but rarely tells you what to do about them. If you already understand glycemic index, meal timing, and glucose physiology, this is fine. If you are new to metabolic health, you may feel overwhelmed with data and under-served by guidance.
Abbott Lingo App
Lingo's app is the most opinionated and directive. Its metabolic coaching engine categorizes each meal into a traffic light system: green (minimal glucose impact), yellow (moderate spike), and red (significant spike). After each flagged meal, Lingo pushes a notification with a specific suggestion.
The "Lingo Score" is a daily composite metric from 0-100 that combines glucose time in range, glucose variability, physical activity, and sleep quality. This gamification works -- we found ourselves genuinely motivated to improve our daily score, which meant choosing lower-glycemic meals and going for post-meal walks.
Lingo's weakness is data depth. Power users who want to export raw glucose data, overlay it with other health metrics, or perform their own analysis will find the app limiting. Lingo wants to be your coach, not your data platform.
Abbott Libre Rio App
Libre Rio's app is the most clinical of the three. It is essentially a consumer-friendly version of the LibreLink app used by diabetes patients worldwide. The interface centers on an Ambulatory Glucose Profile (AGP) -- a standardized clinical report format that shows your glucose distribution over time.
The app provides configurable alerts (high and low thresholds), estimated A1C, time in range statistics, and exportable reports formatted for healthcare provider review. It is not trying to coach you or gamify your behavior -- it is giving you and your doctor the data needed to manage glucose levels.
For its intended audience (people managing or monitoring Type 2 diabetes), Libre Rio's clinical approach is exactly right. For wellness users, it may feel sterile and inaccessible.
The Johns Hopkins Question: Do Non-Diabetics Actually Benefit?
In late 2025, a widely cited Johns Hopkins study followed 300 non-diabetic adults who used OTC CGMs for six months. The findings were sobering:
- 72% discontinued use within six months, citing cost and lack of actionable insights
- Among continuing users, no statistically significant improvement in body weight, A1C, or fasting glucose was observed
- 82% of "glucose spikes" flagged by CGM apps fell within the normal physiological range for non-diabetic individuals
- Participants who continued use reported increased food anxiety at nearly twice the rate of control group participants
The Core Criticism
For metabolically healthy non-diabetics, glucose naturally fluctuates between 70-140 mg/dL throughout the day. These fluctuations are normal physiology, not pathology. CGMs designed for diabetes management flag these variations as "spikes" -- which can cause unnecessary alarm and disordered eating behaviors in people whose glucose regulation is functioning perfectly normally.
This does not mean OTC CGMs are useless for non-diabetics. The study's critics (including Dexcom's chief medical officer) pointed out that the study did not measure behavioral changes like improved dietary awareness, reduced refined carbohydrate consumption, or increased post-meal activity -- all of which have long-term metabolic benefits even if short-term biomarkers don't change.
Who Actually Benefits From OTC CGMs?
Based on our testing and the available evidence, here are the groups most likely to get genuine value:
Strong benefit:
- People with prediabetes (fasting glucose 100-125 mg/dL) who want to understand which foods push them toward diabetic ranges
- Athletes optimizing fueling strategies for training and competition
- People with a family history of Type 2 diabetes who want early metabolic awareness
- Individuals with undiagnosed Type 2 diabetes who can use Libre Rio for confirmation and management
Moderate benefit:
- People curious about their metabolic health who will use the data to make specific dietary changes
- Those experimenting with dietary approaches (keto, low-carb, time-restricted eating) who want glucose data to guide decisions
Limited benefit:
- Metabolically healthy individuals with normal glucose regulation and no specific dietary goals
- People prone to health anxiety or orthorexic tendencies -- CGM data can exacerbate these
✓Pros
- Unprecedented access to personal glucose data without doctor visit
- Real-time feedback on how specific foods affect your body
- Can identify prediabetes or undiagnosed Type 2 diabetes
- Dexcom Stelo excels at pattern education
- Abbott Lingo provides genuinely useful coaching
- Abbott Libre Rio democratizes diabetes management tools
- All three sync with Apple Health for integrated health tracking
✗Cons
- $78-99/month ongoing cost with no insurance coverage
- Most non-diabetics discontinue within 6 months
- Normal glucose fluctuations can cause unnecessary anxiety
- MARD accuracy lower than prescription CGMs
- Sensor application can be uncomfortable for some users
- No long-term evidence of health benefit for non-diabetics
- May promote obsessive food-glucose relationship in susceptible individuals
Our Recommendation by User Type
| User Profile | Best Choice | Why |
|---|---|---|
| Wellness curious, first-time CGM | Abbott Lingo | Active coaching reduces the learning curve; traffic light meal system is immediately actionable |
| Data-driven biohacker | Dexcom Stelo | Best data visualization; pattern analysis; more neutral stance lets you draw your own conclusions |
| Prediabetes or Type 2 risk | Abbott Libre Rio | Clinical-grade reports; configurable alerts; designed for glucose management, not wellness trends |
| Athlete optimizing fueling | Dexcom Stelo | Clean data interface; 5-minute readings; easy food logging for training fuel experiments |
| Budget-conscious user | Abbott Libre Rio | Lowest per-sensor cost at ~$39; most affordable monthly total |
| Sharing data with doctor | Abbott Libre Rio | Built-in AGP reports in the standard format physicians expect |
Sensor Application and Comfort
All three sensors are applied using a spring-loaded applicator that pushes the filament through the skin in a fraction of a second. In our experience, the pain level is comparable to a brief pinch -- less painful than a blood draw, more noticeable than a bandage removal.
We wore sensors on the back of the upper arm (the recommended site for all three). After the initial application:
- Dexcom Stelo: Most secure adhesive. Never peeled during exercise or showering. Slight skin irritation by Day 12.
- Abbott Lingo: Moderate adhesive. Needed supplementary overlay patch during intense exercise by Day 8.
- Abbott Libre Rio: Similar adhesive to Lingo. Stayed secure through daily activities but loosened during swimming by Day 10.
Adhesive Tips for Active Users
If you exercise intensely or swim regularly, apply a transparent adhesive overlay patch (like Simpatch or GrifGrips) over the sensor immediately after application. This extends secure wear through the full sensor life. Avoid applying sensors immediately after showering -- dry skin bonds better.
The Future of OTC CGMs
The OTC CGM market is projected to reach $4.3 billion by 2028, up from an estimated $800 million in 2025. Dexcom and Abbott are both investing in next-generation sensors with smaller form factors, longer wear times (up to 30 days), and integrated multi-analyte sensing that could measure ketones, lactate, and cortisol alongside glucose.
Apple is rumored to be developing a non-invasive optical glucose sensor for future Apple Watch models, though experts estimate this is still 3-5 years from clinical accuracy. If successful, it would disrupt the entire CGM market by eliminating the need for subcutaneous sensors entirely.
Frequently Asked Questions
Frequently Asked Questions
No. All three -- Dexcom Stelo, Abbott Lingo, and Abbott Libre Rio -- are available over the counter without a prescription. You can purchase them online or at participating pharmacies.
Dexcom Stelo and Abbott Lingo are NOT designed or cleared for insulin dosing decisions. If you have Type 1 diabetes, use a prescription CGM (Dexcom G7, Libre 3) that is FDA-cleared for diabetes management. Abbott Libre Rio is designed for Type 2 diabetes management but is not intended for insulin dosing in Type 1 patients.
Most users describe it as a brief pinch lasting less than a second. The applicator uses a spring mechanism that inserts the filament quickly. After insertion, the sensor itself is not painful during wear. Some users experience mild skin irritation from the adhesive after 10-14 days.
Generally no. OTC devices purchased without a prescription are not covered by most health insurance plans or FSA/HSA accounts. If you have diabetes or prediabetes, ask your doctor about a prescription for Dexcom G7 or Libre 3, which are typically covered by insurance.
All three sensors are water-resistant and can be worn in the shower. Swimming is possible but may loosen the adhesive over time. We recommend an overlay adhesive patch for regular swimmers.
OTC CGMs have MARD values of 8.7-9.2%, meaning readings are typically within 9% of a reference blood glucose measurement. This is accurate enough for trend monitoring and dietary decisions but not precise enough for insulin dosing. Finger-prick meters are generally more accurate for single-point readings.
It depends on your goals. If you have prediabetes, a family history of diabetes, or specific dietary optimization goals, a CGM can provide valuable insights. For metabolically healthy individuals with no specific concerns, the evidence for benefit is limited, and the cost is significant. Consider a 1-2 month trial to see if the data changes your behavior before committing long-term.
